Experienced in Multiple Endocrine Neoplasia

Chung-yu D. Chen

National Taiwan University Hospital Yunlin Branch, No. 579, Sec. 2, Yunlin Rd, Yunlin County 640203, 
Douliu, TNQ, TW 
Experienced in Multiple Endocrine Neoplasia
National Taiwan University Hospital Yunlin Branch, No. 579, Sec. 2, Yunlin Rd, Yunlin County 640203, 
Douliu, TNQ, TW 
OverviewLocationsClinical Research

Overview

Chung-yu Chen practices in Douliu, Taiwan. Chen is rated as an Experienced expert by MediFind in the treatment of Multiple Endocrine Neoplasia. Their top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Nontuberculous Mycobacterial Lung Disease, and Non-Small Cell Lung Cancer (NSCLC).

Their clinical research consists of co-authoring 126 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Multiple Endocrine Neoplasia.

Locations

National Taiwan University Hospital Yunlin Branch, No. 579, Sec. 2, Yunlin Rd, Yunlin County 640203, Douliu, TNQ 64020, Taiwan
Other Locations
TPQ 10051, Taiwan
Taipei, TNQ, Taiwan
National Taiwan University Hospital Yunlin Branch, Yunlin County 640, Dawan, TNQ, Taiwan
Taitung, TNQ, Taiwan
Kaohsiung, KHQ, Taiwan
Taoyuan, TNQ, Taiwan
No. 1, Changda Rd, Guiren District, Tainan, TNQ 71101, Taiwan
Hsin Chu Branch Hsinchu 300, Hsinchu, TNQ, Taiwan
Taoyuan City, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3

126 Total Publications

Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer.
Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer.
Journal: Current oncology (Toronto, Ont.)
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chen's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile